1. In the African American population, including people with diabetes, JNC 8 recommends initial antihypertensive therapy with:
A. ACE inhibitor
B. ARB
C. ß-blocker
D. calcium channel blocker
2. For adults with chronic kidney disease and hypertension, the recommended blood pressure goal per JNC 8 is:
A. < 150/90 mmHg
B. < 140/90 mmHg
C. <= 140/90 mmHg
D. < 130/85 mmHg
3. Per the ACCF/AHA guidelines, which of the following agents may be useful to decrease hospitalizations in patients who have stage C heart failure with reduced LVEF?
A. hydralazine/isosorbide dinitrate
B. ACE inhibitors
C. ß-blockers
D. digoxin
4. What are common adverse events of hydralazine/isosorbide dinitrate therapy?
A. headache, dizziness, and gastrointestinal effects
B. fluid retention, urinary tract infection, and dry mouth
C. tachycardia, angina, and nausea
D. dementia, hypotension, and thrombocytopenia
5. All of the following are appropriate dosage regimens for VTE prevention in acutely ill medical patients EXCEPT:
A. enoxaparin 40 mg SC once daily
B. fondaparinux 2.5 mg SC once daily
C. dalteparin 2500 IU SC once daily
D. unfractionated heparin 5000 U SC three times daily
6. A 45-year-old person with diabetes and a LDL level of 150 mg/dL attends your clinic for initial management of hyperlipidemia. As initial therapy, you appropriately recommend:
A. atorvastatin 40 mg
B. simvastatin 80 mg
C. pravastatin 40 mg
D. pitavastatin 2 mg
7. When should a reduction in a statin dosage regimen be considered per the NCEP guidelines?
A. once target LDL goal is achieved
B. for patients on hemodialysis
C. for patients with NYHA class II to IV heart failure
D. if 2 consecutive LDL levels are < 40 mg/dL
8. The two most common signs/symptoms of PAD are:
A. hypertension and pain at rest in the lower extremities
B. pain at rest in the lower extremities and intermittent claudication
C. hyperlipidemia and intermittent claudication
D. thickened toe nails and pain at rest in the lower extremities
9. How often should thyroid function be monitored during amiodarone therapy?
A. at baseline and every 12 months thereafter
B. at baseline and every 3 to 6 months thereafter
C. at baseline and every 6 months thereafter
D. at each clinic visit
10. Which of the following is an appropriate recommendation for secondary prevention of cardioembolic ischemic stroke?
A. aspirin 325 mg daily
B. clopidogrel 75 mg daily
C. dabigatran 150 mg daily
D. warfarin adjusted to an INR = 2.5
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
21. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
22. Will the information presented cause you to change your practice?
A. Yes
B. No
23. Are you committed to making these changes?
A. Yes
B. No
24. As a result of this activity, did you learn something new?
A. Yes
B. No
25. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology/Specialty Pharmacy
I. Industry/Manufacturing
26. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20